Navigation Links
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
Date:7/24/2009

SAN MATEO, Calif., July 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today the preliminary results of a short-term clinical study (Study C123) of Qutenza(TM) in patients with postherpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of the ongoing new drug application (NDA) review, the U.S. Food and Drug Administration (FDA) requested the study to determine whether an FDA-approved topical anesthetic would provide similar tolerability to the topical agent used as a pretreatment in the clinical development program. The NDA for Qutenza in PHN has a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

In Study C123, 24 patients received a single 60-minute Qutenza patch application following a 60-minute pretreatment with an FDA-approved topical anesthetic (2.5% lidocaine / 2.5% prilocaine). The mean duration of patch application was evaluated as the primary endpoint analysis. Patients were monitored for seven days following treatment.

Preliminary results of Study C123 showed the mean duration of patch application was 60.2 minutes, versus a target duration of Qutenza patch application of 60 minutes. No patients removed the Qutenza patch prematurely (i.e.< 90% of the intended full application time).

The company expects to provide results from Study C123 to the FDA prior to the PDUFA date of August 16, 2009. The impact on the agency's timing, if any, for an ultimate decision on the NDA is not yet known.

Dr. Jeffrey Tobias, NeurogesX' Chief Medical Officer commented, "I am grateful to our clinical investigators and the entire NeurogesX team for working together to quickly complete this study. We believe that these results will address the FDA's questions relating to the use of an FDA-approved to
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
4. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
5. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
9. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Encision Inc. (PK:ECIA), a ... dangerous stray electrosurgical burns in minimally invasive surgery, today ... that ended June 30, 2015. The Company ... quarterly net loss of $213 thousand, or $(0.02) per ... million for a net loss of $202 thousand, or ...
(Date:8/3/2015)... , August 3, 2015 ... ) announced today that it has acquired ... Biotherapeutics Inc. for $300 million. With the acquisition, ... ophthalmic drops combining 0.6% povidone iodine (PVP-I) and ... the treatment of infectious conjunctivitis, an ocular surface ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6
... CLEVELAND, Dec. 15 At today,s regular meeting of the board ... the board declared a regular quarterly dividend of 31 cents per ... close of business on February 10, 2010. , About The ... ) is an innovative specialty chemical company that produces and supplies ...
... , , , , ... VAR ) announced today that it will report results for first ... Wednesday, January 27, 2010. The news release will be followed by ... The news release and a link to the conference call webcast will ...
Cached Medicine Technology:Lubrizol Declares Dividend 2Varian Medical Systems Schedules First Quarter FY2010 News Release and Conference Call 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... amputation , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) ... Impossible – an organization whose mission is to develop technology for the sake ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its least visited ... untapped ground water aquifers, whose main outflow is at Ahjumawi Lava Springs, part ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 13 article from The Daily Mail titled ... Natural Painkiller That Can Last 'For Five Weeks'" discusses the use of stem ... study showed that harvesting stem cell-rich bone marrow from the hip, known as bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris ... Hospital Emergency Room – Gilbert, opening in August. The new facility is licensed ... the West Valley. , “Dr. Baldwin is an excellent leader and will ensure ...
Breaking Medicine News(10 mins):Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... to Educate Health Care Stakeholders , ... The Virginia Business Coalition on Health (VBCH) announced ... reform efforts initiated by the Center for Medicare and ... "Never Events" - serious and costly preventable hospital errors. ...
... Consumer Watchdog said the health insurance industry,s support today ... it includes a requirement that every American buy insurance ... self-serving. The proposal amounts only to a customer delivery ... will not solve America,s health care problems and will ...
... BOULDER--The University Corporation for Atmospheric Research (UCAR), working ... organizations, is launching a project this month to ... Africa to help reduce outbreaks of meningitis. The ... vaccination programs more effectively for this deadly disease, ...
... Global Programs Required by New Legislation , ... United BioSource Corporation,s (UBC) Annette Stemhagen, DrPH, FISPE, and ... and Drug Safety Summit held in Washington, DC, on ... Director, CDER, FDA; Jane Axelrad, Associate Director for Policy, ...
... (NYSE:, LLY ) and the International Council of ... Chamber of Commerce Business Civic Leadership Center,(BCLC),s 9th annual ... Lilly and ICN were recognized for their groundbreaking work ... worldwide. A unique voting system landed Lilly and ...
... Nov. 19 Par Pharmaceutical,Companies, Inc. (NYSE: PRX ... distribution agreement with AstraZeneca in the U.S. to market budesonide,inhalation ... for the maintenance treatment of asthma. Par began,shipping 0.25 ... , Full-year US sales ...
Cached Medicine News:Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 2Health News:Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement 3Health News:Consumer Watchdog Comments on Health Insurer's Self-Serving Support of 'Individual Mandate' 2Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 2Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 3Health News:United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit 2Health News:United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit 3Health News:Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center 2Health News:Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center 3Health News:Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: